BNP Paribas Financial Markets
ARCT icon

BNP Paribas Financial Markets’s Arcturus Therapeutics ARCT Stock Holding History

BNP Paribas Financial Markets’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Buy
261,789
+66,929
+34% +$528K ﹤0.01% 2902
2026
Q1 		$1.5M Buy
194,860
+48,093
+33% +$351K ﹤0.01% 2851
2025
Q4 		$900K Buy
146,767
+139,919
+2,043% +$1.51M ﹤0.01% 3184
2025
Q3 		$126K Buy
6,848
+2,679
+64% +$43K ﹤0.01% 4200
2025
Q2 		$54.2K Buy
4,169
+2,586
+163% +$30.6K ﹤0.01% 4232
2025
Q1 		$16.8K Sell
1,583
-1,155
-42% -$18.3K ﹤0.01% 4585
2024
Q4 		$46.5K Sell
2,738
-13,093
-83% -$246K ﹤0.01% 4456
2024
Q3 		$367K Buy
15,831
+14,330
+955% +$307K ﹤0.01% 2978
2024
Q2 		$36.5K Sell
1,501
-12,753
-89% -$387K ﹤0.01% 3528
2024
Q1 		$481K Sell
14,254
-9,005
-39% -$319K ﹤0.01% 2862
2023
Q4 		$733K Buy
23,259
+682
+3% +$16.2K ﹤0.01% 2580
2023
Q3 		$577K Sell
22,577
-6,814
-23% -$210K ﹤0.01% 2646
2023
Q2 		$843K Sell
29,391
-2,461
-8% -$67K ﹤0.01% 2310
2023
Q1 		$763K Buy
31,852
+6,648
+26% +$119K ﹤0.01% 2485
2022
Q4 		$427K Sell
25,204
-35,149
-58% -$613K ﹤0.01% 2675
2022
Q3 		$894K Buy
60,353
+55,310
+1,097% +$928K ﹤0.01% 2574
2022
Q2 		$79.4K Buy
5,043
+1,956
+63% +$38.4K ﹤0.01% 3425
2022
Q1 		$83.2K Sell
3,087
-8,518
-73% -$217K ﹤0.01% 3415
2021
Q4 		$430K Buy
11,605
+6,222
+116% +$254K ﹤0.01% 3078
2021
Q3 		$257K Buy
5,383
+2,711
+101% +$121K ﹤0.01% 2960
2021
Q2 		$90.4K Sell
2,672
-2,421
-48% -$82K ﹤0.01% 3074
2021
Q1 		$210K Buy
5,093
+2,387
+88% +$142K ﹤0.01% 3022
2020
Q4 		$117K Sell
2,706
-1,427
-35% -$96.7K ﹤0.01% 3133
2020
Q3 		$177K Buy
4,133
+3,637
+733% +$181K ﹤0.01% 2815
2020
Q2 		$23.2K Buy
+496
New +$17.1K ﹤0.01% 3335

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BNP Paribas Financial Markets's ARCT Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Arcturus Therapeutics (ARCT) stake by 34% in Q2 2026, buying an estimated $528K and bringing the position to 261,789 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2902.

BNP Paribas Financial Markets first reported a position in ARCT in Q2 2020 and has held it in 25 quarters since. 125 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • BNP Paribas Financial Markets held 261,789 shares of Arcturus Therapeutics worth $1.76M as of Q2 2026.
  • BNP Paribas Financial Markets bought 66,929 Arcturus Therapeutics shares in Q2 2026, an estimated $528K.
  • Arcturus Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #2902 holding.
  • BNP Paribas Financial Markets first reported a position in Arcturus Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • 125 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.